Clofazimine Exposure

Antitubercular Agents / pharmacology Clofazimine / pharmacology Diarylquinolines / pharmacology Drug Resistance, Multiple, Bacterial / genetics Membrane Transport Proteins / genetics Microbial Sensitivity Tests Mycobacterium tuberculosis / drug effects Tuberculosis, Multidrug-Resistant / drug therapy
bedaquiline clofazimine cross-resistance efflux pump mutants

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
03 2019
Historique:
received: 13 10 2018
accepted: 31 12 2018
pubmed: 16 1 2019
medline: 19 2 2020
entrez: 16 1 2019
Statut: epublish

Résumé

Six

Identifiants

DOI: 10.1128/AAC.02141-18 PMID: 30642938 PMC: PMC6395909
pubmed: 30642938
pii: AAC.02141-18
doi: 10.1128/AAC.02141-18
pmc: PMC6395909
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Diarylquinolines 0
Membrane Transport Proteins 0
bedaquiline 78846I289Y
Clofazimine D959AE5USF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

PLoS One. 2014 Jul 10;9(7):e102135
pubmed: 25010492
Lancet Infect Dis. 2016 Oct;16(10):1185-1192
pubmed: 27397590
Nat Rev Drug Discov. 2013 May;12(5):388-404
pubmed: 23629506
Antimicrob Agents Chemother. 2014 May;58(5):2979-81
pubmed: 24590481
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28739779
J Microbiol Methods. 2018 Oct;153:1-9
pubmed: 30165087
J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906
pubmed: 28387862
J Antimicrob Chemother. 2015 Sep;70(9):2507-10
pubmed: 26045528
Antimicrob Agents Chemother. 2006 Aug;50(8):2853-6
pubmed: 16870785
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690
pubmed: 28031270
Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8
pubmed: 20038615
Science. 2005 Jan 14;307(5707):223-7
pubmed: 15591164
Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92
pubmed: 20442432
BMC Genomics. 2015 Oct 24;16:857
pubmed: 26496891
Antimicrob Agents Chemother. 2014;58(1):574-6
pubmed: 24126586

Auteurs

Nabila Ismail (N)

Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa nabilai@nicd.ac.za.

Remco P H Peters (RPH)

Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Department of Medical Microbiology, School for Public Health and Primary Care (CAPRHI), Maastricht University, Maastricht, The Netherlands.
ORCID: 0000-0003-2124-7275

Nazir A Ismail (NA)

Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Centre for Tuberculosis, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.

Shaheed V Omar (SV)

Centre for Tuberculosis, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.

Articles similaires

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Menthol as an effective inhibitor of quorum sensing and biofilm formation in Candida albicans and Candida glabrata by targeting the transcriptional repressor TUP1.

Pouria Khodavandi, Maryam Miri Soogh, Fahimeh Alizadeh et al.
1.00
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol

Naturally derived 3-aminoquinuclidine salts as new promising therapeutic agents.

Doris Crnčević, Alma Ramić, Andreja Radman Kastelic et al.
1.00
Humans Microbial Sensitivity Tests Anti-Bacterial Agents Biofilms Quinuclidines

Prevalence of Salmonella Typhi, its associated factors and antimicrobial susceptibility profile among patients attending Hawassa University Comprehensive Specialized Hospital, Hawassa, Ethiopia.

Teketel Simion, Alegntaw Abate, Tsegaye Alemayehu et al.
1.00
Humans Ethiopia Salmonella typhi Male Cross-Sectional Studies

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Clofazimine Exposure
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › Phénazines › Clofazimine › Clofazimine Exposure
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Diarylquinoléines › Clofazimine Exposure
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › Clofazimine Exposure
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Clofazimine Exposure
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Clofazimine Exposure
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Clofazimine Exposure
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › Clofazimine Exposure